|
|
以色列研究：南非变种病毒可突破辉瑞疫苗
文 / 林煇智发布 / 2021年4月11日 9:23 PM
（早报讯）以色列研究机构研究显示，南非发现的变种病毒在一定程度上能“突破”辉瑞疫苗的防护网。不过该研究尚未经过同行评审。
路透社报道，特拉维夫大学及以色列医疗服务机构克拉利特研究所周六（10日）公布的最新研究，团队将800名冠病患者分成两批，一批是没有接种疫苗的确诊者，另一批则是接种了一剂或两剂辉瑞疫苗14天后仍感染的确诊者。
研究发现，研究对象中1％感染的是南非发现的变种病毒，其中，接种了两剂辉瑞疫苗后仍确诊的患者，感染该变种病毒的机率是未接种疫苗者的近八倍，感染率分别为5.4％和0.7％。
特拉维夫大学专家斯特恩称，和未接种疫苗的患者相比，接种两剂疫苗的患者感染南非发现的变种病毒的几率更高。这意味该变种病毒在一定程度上能够“突破”辉瑞疫苗的保护作用。
不过研究人员也强调，由于南非发现的变种病毒在以色列的感染率较低，这项研究样本不多，也无法推论出辉瑞疫苗对该变种病毒的整体保护效力。此研究也尚未经过同行评审。辉瑞及德国BioNTech公司尚未对此发表评论。
据报道，辉瑞和BioNTech公司今年4月1日曾表示，他们生产的疫苗在预防冠病病毒上有效率高达91％，并在加入了新的临床数据后声称，疫苗对南非发现的变种病毒有效。
http://www.aswetalk.net/bbs/foru ... wthread&fid=167
========================
South African variant may evade protection from Pfizer vaccine, Israeli study says
By Maayan Lubell
4 MIN READ
JERUSALEM (Reuters) -The coronavirus variant discovered in South Africa may evade the protection provided by Pfizer/BioNTech’s COVID-19 vaccine to some extent, a real-world data study in Israel found, though its prevalence in the country is very low and the research has not been peer reviewed.
The study, released on Saturday, compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated patients with the disease.
It matched age and gender, among other characteristics.
The South African variant, B.1.351, was found to make up about 1% of all the COVID-19 cases across all the people studied, according to the study by Tel Aviv University and Israel’s largest healthcare provider, Clalit.
But among patients who had received two doses of the vaccine, the variant’s prevalence rate was eight times higher than those unvaccinated - 5.4% versus 0.7%.
This suggests the vaccine is less effective against the South African variant, compared with the original coronavirus and a variant first identified in Britain that has come to comprise nearly all COVID-19 cases in Israel, the researchers said.
“We found a disproportionately higher rate of the South African variant among people vaccinated with a second dose, compared to the unvaccinated group. This means that the South African variant is able, to some extent, to break through the vaccine’s protection,” said Tel Aviv University’s Adi Stern.
The researchers cautioned, though, that the study only had a small sample size of people infected with the South African variant because of its rarity in Israel.
They also said the research was not intended to deduce overall vaccine effectiveness against any variant, since it only looked at people who had already tested positive for COVID-19, not at overall infection rates.
Pfizer declined to comment on the Israeli study.
Pfizer and BioNTech said on April 1 that their vaccine was around 91% effective at preventing COVID-19, citing updated trial data that included participants inoculated for up to six months.
Training nurse Sari Roos prepares a dose of Pfizer/BioNTech vaccine against coronavirus disease (COVID-19) to teach her air bubble technique in Laakso hospital in Helsinki, Finland March 11, 2021. Picture taken March 11, 2021. REUTERS/Essi Lehto
They have been testing a third dose of their shot as a booster, and have said they could modify the shot to specifically address new variants if needed.
In respect to the South African variant, they said that among a group of 800 study volunteers in South Africa, where B.1.351 is widespread, there were nine cases of COVID-19, all of which occurred among participants who got the placebo. Of those nine cases, six were among individuals infected with the South African variant.
Some previous studies have indicated that the Pfizer/BioNTech shot was less potent against the B.1.351 variant than against other variants of the coronavirus, but still offered a robust defence.
VARIANT IS NOT WIDESPREAD
While the results of the study may cause concern, the low prevalence of the South African strain was encouraging, according to Tel Aviv University’s Stern.
“Even if the South African variant does break through the vaccine’s protection, it has not spread widely through the population,” said Stern, adding that the British variant may be “blocking” the spread of the South African strain.
Almost 53% of Israel’s 9.3 million population has received both Pfizer doses. Israel has largely reopened its economy in recent weeks while the pandemic appears to be receding, with infection rates, severe illness and hospitalizations dropping sharply.
About a third of Israelis are below the age of 16, which means they are still not eligible for the shot.
Reporting by Maayan LubellEditing by Pravin Char and Frances Kerry
https://www.reuters.com/article/ ... study-idUSKBN2BX0JX
===================================
上面是新加坡《联合早报》的报导，下面是路透社的报导。“突破”是break through的直译。
疑问在于：
研究发现，研究对象中1％感染的是南非发现的变种病毒，其中，接种了两剂辉瑞疫苗后仍确诊的患者，感染该变种病毒的机率是未接种疫苗者的近八倍，感染率分别为5.4％和0.7％。
这应该怎么解读？
0.7%应该是人口中感染南非病毒的比率。400人的样本小了点，但还是有点意义。
要是辉瑞只是对南非变种不管用，那是一回事；要是接种之后反而容易受到南非变种的感染，那就是另一回事了。
AZ已经翻车了，辉瑞也要翻车？ |
|
雷达卡
楼主
收藏
分享
淘帖
支持
反对
提升卡
置顶卡
沉默卡
喧嚣卡
变色卡
抢沙发
千斤顶
显身卡
发表于 2021-4-12 04:11:06
